Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Mesenchymal stem cells: new approaches for the treatment of neurological diseases.

Momin EN., Mohyeldin A., Zaidi HA., Vela G., Quiñones-Hinojosa A.

Clinical Trial on Back & Spine, published in Curr Stem Cell Res Ther (2010) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Curr Stem Cell Res Ther (2010)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
20528757
DOI
10.2174/157488810793351631

Abstract (original English)

Cellular therapies represent a new frontier in the treatment of neurological disease. Mesenchymal stem cells (MSCs), which can be harvested from bone marrow, adipose tissue, and umbilical cord blood, among many other sources, possess several qualities which may be used to treat diseases of the central nervous system. MSCs migrate to sites of malignancy, a property which may be used for the treatment of brain cancer. MSCs possess immunosuppressive properties, which may be used for the treatment of neurological disorders with an inflammatory etiology. Finally, MSCs restore injured neural tissue, a property which may be used for the treatment of neural injury. Approximately 23 clinical trials have been completed to date, with many more ongoing, and all have been listed in this review. The long-term safety of MSC-based therapies is not well established, and continues to be one major limitation to clinical translation. More broadly, only a small minority of clinical trials have employed rigorous designs that include prospective randomization, patients from multiple centers, clinically-relevant and reproducible endpoints, and adequate long-term follow-up. These limitations must be addressed before MSCs can enter widespread clinical use. Nevertheless, MSCs represent a promising new approach to treating diseases of the central nervous system that are traditionally associated with morbi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsBrain NeoplasmsCell MovementClinical Trials as TopicHumansImmunosuppression TherapyMesenchymal Stem Cell TransplantationMesenchymal Stem CellsNervous System DiseasesSpinal Cord Injuries

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research